IMDX on Nasdaq

Insight Molecular Diagnostics Inc.

We are a pioneering diagnostics technology company.5 From its latest annual report

$2.95 up 0.16 (5.73%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

Compare with BIOMERICA INC, Anbio Biotechnology or Aspira Women's Health Inc., or pick any stock.

  • TickerIMDX on Nasdaq2
  • IndustryIn Vitro & In Vivo Diagnostic Substances2
  • HeadquartersSacramento, United States2
  • Incorporated inCA4
  • Business address2 International Plaza Dr., Suite 510, Nashville, Tn 372174
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI549300BIYAW8GO4102872
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o KOY SAECHAO, 2710 GATEWAY OAKSDRIVE, 95833 Sacramento, United States2
  • Registered withSecretary of State, 32317382

See how the biggest companies compare on our leaderboards

We are a pioneering diagnostics technology company. Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

56.7%Gross margin6
-1260.8%Operating margin6
-1238.5%Net margin6
115.6%Revenue growth, 20256
-$25.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Laboratory Services brought in 99% of the revenue Insight Molecular Diagnostics Inc. broke down this way in fiscal 2025.

  1. Laboratory Services$4.0M699%up 117% from 2024
  2. Kitted Products$24.0K61%
Products and services by year
Products and services20242025
Laboratory Services$1.9M$4.0M
Kitted Products$0$24.0K

Regions

United States brought in 99% of the revenue Insight Molecular Diagnostics Inc. broke down this way in fiscal 2025.

  1. United States$4.0M699%up 141% from 2024
  2. Europe$24.0K61%up 33% from 2024
Regions by year
Regions20242025
United States$1.7M$4.0M
Europe$18.0K$24.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue10¢$1.8M
  • Research and development90¢$15.9M

Out of $4.1M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$4.1M in 2025+233% since 2020
0$2.0M$4.0M$6.0M2020: $1.2M$1.2M20202021: $2.2M$2.2M2021+81%2022: $958.0K$958.0K2022−56%2023: $1.5M$1.5M2023+57%2024: $1.9M$1.9M2024+25%2025: $4.1M$4.1M2025+116%
Gross profit789106$2.3M in 2025
-$1.0M0$1.0M$2.0M$3.0M2020: -$639.0K-$639.0K20202021: $1.4M$1.4M20212022: -$18.0K-$18.0K20222023: $413.0K$413.0K20232024: $740.0K$740.0K2024+79%2025: $2.3M$2.3M2025+211%
Operating income11789106-$51.1M in 2025+130% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$22.2M-$22.2M20192020: -$29.7M-$29.7M2020+34%2021: -$53.7M-$53.7M2021+81%2022: -$18.0M-$18.0M2022−67%2023: -$25.1M-$25.1M2023+40%2024: -$61.0M-$61.0M2024+143%2025: -$51.1M-$51.1M2025−16%
Net income11789106-$50.2M in 2025+124% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$22.4M-$22.4M20192020: -$29.9M-$29.9M2020+33%2021: -$64.1M-$64.1M2021+114%2022: -$72.9M-$72.9M2022+14%2023: -$27.8M-$27.8M2023−62%2024: -$60.7M-$60.7M2024+118%2025: -$50.2M-$50.2M2025−17%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Net revenue$4.1M$1.9M
Cost of revenues$1.8M$1.1M
Cost of revenues amortization of acquired intangibles$7.0K$88.0K
Gross profit$2.3M$740.0K
Research and development$15.9M$9.8M
Sales and marketing$6.3M$3.9M
General and administrative$10.6M$10.2M
Change in fair value of contingent consideration$5.9M-$4.3M
Impairment losses$14.6M$41.9M
Impairment loss on held for sale assets$0$169.0K
Total operating expenses$53.4M$61.8M
Loss from operations-$51.1M-$61.0M
Interest expense-$109.0K-$84.0K
Other income, net$1.0M$462.0K
Total other income, net$902.0K$378.0K
Loss before income taxes-$50.2M-$60.7M
Income taxes$0$0
Net loss-$50.2M-$60.7M
Net loss attributable to common stockholders - basic-$50.2M-$60.9M
Net loss attributable to common stockholders - diluted-$50.2M-$60.9M
Net loss attributable to common stockholders per share - basic-$1.65-$4.66
Net loss attributable to common stockholders per share - diluted-$1.65-$4.66
Weighted average shares outstanding - basic30.5M shares13.1M shares
Weighted average shares outstanding - diluted30.5M shares13.1M shares

Compare Insight Molecular Diagnostics Inc. with another company

Leadership

Who has led Insight Molecular Diagnostics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William Annett2015–2019
  2. Ronald Asbury Andrews2019–2022
  3. Josh Riggs2022–now

President

  1. William Annett2015–2019
  2. Ronald Asbury Andrews2020–2022
  3. Gisela Paulsen2022
  4. Josh Riggs2023–now

Chief financial officer

  1. Russell Skibsted2015
  2. Mitchell S. Levine2017–2022
  3. Anish M. John2022–2023
  4. Andrea S. James2024–now

Chief operating officer

  1. Gisela Paulsen2021–2022
20202025
Board members and other officers (20)

Former names

  • OncoCyte CorpFeb 6, 2020 to Jun 17, 20254

Timeline

  1. Dec 9, 2022New chief executive Josh Riggs becomes CEO14
  2. Jul 3, 2019New chief executive Ronald Asbury Andrews becomes CEO15
  3. Dec 30, 2015New chief executive William Annett becomes CEO16
  4. Sep 30, 2009Founded Insight Molecular Diagnostics Inc. is founded2

Filings

299 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 83 major events, 117 insider forms, 26 large holders, 3 private raises, 48 other. The latest 20:

  1. Sep 21, 20268-K EDGAR
  2. Aug 10, 202610-Q EDGAR
  3. Aug 10, 20268-K EDGAR
  4. Jul 24, 2026S-8 EDGAR
  5. Jul 6, 20264 EDGAR
  6. Jul 6, 20264 EDGAR
  7. Jul 6, 20264 EDGAR
  8. Jun 17, 20268-K EDGAR
  9. Jun 15, 20264 EDGAR
  10. Jun 15, 20264 EDGAR
  11. Jun 15, 20264 EDGAR
  12. May 13, 202610-Q EDGAR
  13. May 13, 20268-K EDGAR
  14. May 13, 20268-K/A EDGAR
  15. Apr 30, 2026ARS EDGAR
  16. Apr 30, 2026DEFA14A EDGAR
  17. Apr 30, 2026DEF 14A EDGAR
  18. Apr 30, 20268-K EDGAR
  19. Apr 27, 2026SCHEDULE 13D/A EDGAR
  20. Apr 27, 20264 EDGAR

The 299 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 48 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 27, 2026BROADWOOD PARTNERS, L.P.10% ownerBuy250,923$3.64$913.4KForm 4
Apr 24, 2026BROADWOOD PARTNERS, L.P.10% ownerBuy38,880$3.53$137.2KForm 4
Apr 23, 2026BROADWOOD PARTNERS, L.P.10% ownerBuy280,381$3.50$981.3KForm 4
Apr 20, 2026BROADWOOD CAPITAL INC10% ownerBuy40,690$3.88$157.9KForm 4
Apr 17, 2026BROADWOOD CAPITAL INC10% ownerBuy40,114$3.57$143.2KForm 4
Apr 16, 2026BROADWOOD CAPITAL INC10% ownerBuy102,057$3.45$352.1KForm 4
Feb 10, 2026Bradsher Neal C10% ownerBuy521,739$5.75$3.0MForm 4
Feb 7, 2025James Andrea S.Chief Financial OfficerBuy97,561$2.05$200.0KForm 4
Feb 7, 2025SMITH PATRICK W10% ownerBuy1,077,600$2.05$2.2MForm 4
Feb 6, 2025BROADWOOD PARTNERS, L.P.10% ownerBuy5,165,695$2.05$10.6MForm 4
Feb 4, 2025SMITH PATRICK W10% ownerBuy25$2.02$50Form 4
Jan 31, 2025SMITH PATRICK W10% ownerBuy890$2.01$1.8KForm 4
Jan 30, 2025SMITH PATRICK W10% ownerBuy318$2.01$639Form 4
Jan 29, 2025SMITH PATRICK W10% ownerBuy3,880$2.01$7.8KForm 4
Jan 14, 2025SMITH PATRICK W10% ownerBuy10,386$2.15$22.3KForm 4
Jan 13, 2025SMITH PATRICK W10% ownerBuy5,669$2.08$11.8KForm 4
Dec 26, 2024SMITH PATRICK W10% ownerBuy90,219$2.13$192.2KForm 4
Dec 26, 2024Arno AndrewDirectorBuy12,500$2.11$26.4KForm 4
Dec 5, 2024James Andrea S.Chief Financial OfficerBuy20,000$2.29$45.8KForm 4
Oct 2, 2024James Andrea S.Chief Financial OfficerBuy33,670$2.97$100.0KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 10, 2025Raised $21.7 million in a private offering of equity Form D: 12 investors so far Form D
  2. Oct 2, 2024Raised $10.2 million in a private offering of equity Form D: 16 investors so far Form D
  3. Apr 11, 2024Raised $15.8 million in a private offering of equity Form D: 21 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 39. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Broadwood Capital Inc12,684,884$74.8M3.9%+753,045
AWM Investment Company, Inc.2,836,692$16.7M1.5%+30,436
Vanguard Capital Management LLC735,847$4.3M0.0%+198,686
Pura Vida Investments, LLC484,845$2.9M7.7%−462,289
Family Office Research LLC368,849$2.2M0.8%+241,583
Geode Capital Management, LLC256,903$1.5M0.0%−5,150
Jane Street Group, LLC157,682$930.3K0.0%New
BlackRock, Inc.150,521$888.1K0.0%+15,176
Vanguard Fiduciary Trust Co124,576$735.0K0.0%−8,015
State Street Corp92,124$543.5K0.0%+41,370
Millennium Management LLC82,499$486.7K0.0%−20,971
UBS Group AG53,276$314.3K0.0%+30,525
Northern Trust Corp49,090$289.6K0.0%No change
Osaic Holdings, Inc.39,136$230.9K0.0%+15,001
Morgan Stanley35,515$209.5K0.0%−573
Jefferies Financial Group Inc.18,100$106.8K0.0%New
Marshall Wace, Llp16,597$97.9K0.0%New
ExodusPoint Capital Management, LP14,029$82.8K0.0%New
Axq Capital, LP13,407$79.1K0.0%New
Flatrock Wealth Partners LLC13,044$77.0K0.0%No change
Two Sigma Investments, LP11,101$65.5K0.0%New
XTX Topco Ltd10,743$63.4K0.0%−19,610
Private Advisor Group, LLC10,416$61.5K0.0%No change
Bnp Paribas Financial Markets5,801$34.2K0.0%+5,737
Vanguard Global Advisers, LLC5,775$34.1K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Yahoo FinanceIMDX quote
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49